Literature DB >> 28993158

High-potency block of Kir4.1 channels by pentamidine: Molecular basis.

Iván A Aréchiga-Figueroa1, Leticia G Marmolejo-Murillo2, Meng Cui3, Mayra Delgado-Ramírez4, Marcel A G van der Heyden5, José A Sánchez-Chapula2, Aldo A Rodríguez-Menchaca6.   

Abstract

Inward rectifier potassium (Kir) channels are expressed in almost all mammalian tissues and contribute to a wide range of physiological processes. Kir4.1 channel expression is found in the brain, inner ear, eye, and kidney. Loss-of-function mutations in the pore-forming Kir4.1 subunit cause an autosomal recessive disorder characterized by epilepsy, ataxia, sensorineural deafness and tubulopathy (SeSAME/EST syndrome). Despite its importance in physiological and pathological conditions, pharmacological research of Kir4.1 is limited. Here, we characterized the effect of pentamidine on Kir4.1 channels using electrophysiology, mutagenesis and computational methods. Pentamidine potently inhibited Kir4.1 channels when applied to the cytoplasmic side under inside-out patch clamp configuration (IC50 = 97nM). The block was voltage dependent. Molecular modeling predicted the binding of pentamidine to the transmembrane pore region of Kir4.1 at aminoacids T127, T128 and E158. Mutation of each of these residues reduced the potency of pentamidine to block Kir4.1 channels. A pentamidine analog (PA-6) inhibited Kir4.1 with similar potency (IC50 = 132nM). Overall, this study shows that pentamidine blocks Kir4.1 channels interacting with threonine and glutamate residues in the transmembrane pore region. These results can be useful to design novel compounds with major potency and specificity over Kir4.1 channels.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kir4.1; Molecular modeling; Mutagenesis; PA-6; Pentamidine

Mesh:

Substances:

Year:  2017        PMID: 28993158     DOI: 10.1016/j.ejphar.2017.10.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  In vitro and in silico characterization of the inhibition of Kir4.1 channels by aminoglycoside antibiotics.

Authors:  Rita Morán-Zendejas; Mayra Delgado-Ramírez; Jie Xu; Belkis Valdés-Abadía; Iván A Aréchiga-Figueroa; Meng Cui; Aldo A Rodríguez-Menchaca
Journal:  Br J Pharmacol       Date:  2020-08-17       Impact factor: 8.739

2.  VU6036720: The First Potent and Selective In Vitro Inhibitor of Heteromeric Kir4.1/5.1 Inward Rectifier Potassium Channels.

Authors:  Samantha J McClenahan; Caitlin N Kent; Sujay V Kharade; Elena Isaeva; Jade C Williams; Changho Han; Andrew Terker; Robert Gresham; Roman M Lazarenko; Emily L Days; Ian M Romaine; Joshua A Bauer; Olivier Boutaud; Gary A Sulikowski; Raymond Harris; C David Weaver; Alexander Staruschenko; Craig W Lindsley; Jerod S Denton
Journal:  Mol Pharmacol       Date:  2022-03-03       Impact factor: 4.054

3.  Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity.

Authors:  Mohammad A K Azad; Julie L M Moreau; Jing Lu; Yan Zhu; Xukai Jiang; Mary Tonta; Rachel Lam; Hasini Wickremasinghe; Jinxin Zhao; Jiping Wang; Harold A Coleman; Luke E Formosa; Tony Velkov; Helena C Parkington; Alexander N Combes; Joseph Rosenbluh; Jian Li
Journal:  Cell Mol Life Sci       Date:  2022-05-15       Impact factor: 9.207

4.  Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992.

Authors:  Sujay V Kharade; Haruto Kurata; Aaron M Bender; Anna L Blobaum; Eric E Figueroa; Amanda Duran; Meghan Kramer; Emily Days; Paige Vinson; Daniel Flores; Lisa M Satlin; Jens Meiler; C David Weaver; Craig W Lindsley; Corey R Hopkins; Jerod S Denton
Journal:  Mol Pharmacol       Date:  2018-06-12       Impact factor: 4.436

Review 5.  Inwardly Rectifying Potassium Channel Kir4.1 as a Novel Modulator of BDNF Expression in Astrocytes.

Authors:  Yukihiro Ohno; Masato Kinboshi; Saki Shimizu
Journal:  Int J Mol Sci       Date:  2018-10-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.